Roflumilast
Rank #398 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$22.8M
Total Cost
97,022
Total Claims
$22.8M
Total Cost
3,651
Prescribers
$235
Cost per Claim
8,902
Beneficiaries
134,918
30-Day Fills
$6,255
Avg Cost/Provider
27
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$22.8M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $22.8M total
Top Prescribers of Roflumilast
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Jason Karp | Pulmonary Disease | Lake Success, NY | 251 | $86K |
| 2 | Ganesha Santhyadka | Pulmonary Disease | Bangor, ME | 381 | $84K |
| 3 | Mir-Omar Ali | Pulmonary Disease | Clayton, NC | 506 | $83K |
| 4 | Mohammad Tariq | Pulmonary Disease | Kokomo, IN | 441 | $73K |
| 5 | Jitendrakumar Gupta | Pulmonary Disease | Sioux City, IA | 238 | $66K |
| 6 | Christy Martin | Nurse Practitioner | Portsmouth, OH | 130 | $65K |
| 7 | Shahla Naoman | Pulmonary Disease | Batesville, AR | 275 | $59K |
| 8 | Timothy Killeen | Internal Medicine | Temecula, CA | 184 | $56K |
| 9 | Jillian Eastman | Nurse Practitioner | Syracuse, NY | 220 | $52K |
| 10 | Umer Siddiqui | Pulmonary Disease | Washington, MO | 229 | $52K |
| 11 | Ganesha Santhyadka | Pulmonary Disease | Bangor, ME | 88 | $51K |
| 12 | Jillian Eastman | Nurse Practitioner | Syracuse, NY | 80 | $50K |
| 13 | Donna Romito | Pulmonary Disease | Norwich, CT | 115 | $50K |
| 14 | Sheila Gonzalez | Pulmonary Disease | Middleburg, FL | 181 | $49K |
| 15 | Stephen Chen | Critical Care (Intensivists) | Monterey Park, CA | 212 | $47K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 395 | Droxidopa (Droxidopa) | $23.4M | 9,058 |
| 396 | Fenofibrate Nanocrystallized (Fenofibrate) | $23.2M | 602,181 |
| 397 | Ravulizumab-Cwvz (Ultomiris) | $23.1M | 428 |
| 398 | Roflumilast (Roflumilast) | $22.8M | 97,022 |
| 399 | Romosozumab-Aqqg (Evenity (2 Syringes)) | $22.3M | 9,087 |
| 400 | Azithromycin (Azithromycin) | $22.2M | 3,009,458 |
| 401 | Torsemide (Torsemide) | $22.2M | 971,579 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology